Treatment Initiation within the Therapeutic Window of Opportunity in Acute Uveitic Phase of Vogt-Koyanagi-Harada Disease Preserves Photoreceptor Function

ABSTRACT Purpose To evaluate central retinal sensitivity in patients with initial-onset acute uveitis associated with Vogt–Koyanagi–Harada (VKH) disease treated within (early presentation) or outside (late presentation) the therapeutic window of opportunity after discontinuation of immunosuppressive therapy without relapse of inflammation. Methods In this retrospective study, 19 patients (38 eyes) presented in the phase preceding anterior segment (AS) inflammation (early presentation) and 17 patients (33 eyes) had AS inflammation at presentation (late presentation). MP-1 microperimetric evaluation of retinal sensitivity in the central 12 degrees was assessed at last follow-up after treatment. Results The median follow-up period, duration of treatment, and interval between discontinuation of treatment and last follow-up were 20, 16.5, and 6 months, respectively. None of the eyes in the early presentation group developed “sunset glow fundus” (SGF), whereas in the late presentation group, 81.8% of the eyes developed SGF (p < 0.001). Mean retinal sensitivity was significantly worse in the late presentation group and in the eyes that developed SGF (p < 0.001 for both comparisons). Conclusions Prompt institution of effective immunosuppressive therapy within the therapeutic window of opportunity preserves photoreceptor function.

• Publication year

  2026

• Venue

  Ocular immunology and inflammation

• Publication date

  2026-02-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/09273948.2025.2600579PMID 41632905
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Quantitative Assessment of Swept-Source Optical Coherence Tomography Angiography in VKH Patients Across Different Disease stages.

  2025cited by this paper
• Comparisons of choroidal blood flow velocity between initial-onset acute uveitis associated with Vogt–Koyanagi–Harada disease and acute central serous chorioretinopathy

  2023cited by this paper
• Therapeutic window of opportunity in the acute uveitic phase of Vogt–Koyanagi–Harada disease: Prevention of late autoimmune complications by early intervention

  2022influential reference
• Changes in ocular blood flow and retinal oxygen metabolism during immunosuppressive therapy for initial‐onset acute uveitis associated with Vogt–Koyanagi–Harada disease

  2022cited by this paper
• Effect of immunosuppressive therapy on ocular blood flow in initial‐onset acute uveitis associated with Vogt–Koyanagi–Harada disease

  2021cited by this paper
• Remnant Epitopes Generating Autoimmunity: From Model to Useful Paradigm.

  2020cited by this paper
• Three-dimensional analysis of choroidal vessels in eyes with Vogt-Koyanagi-Harada disease before and after treatment.

  2020cited by this paper
• Incidence, Risk Factors and Surgical Outcomes of Cataract among Patients with Vogt-Koyanagi-Harada Disease

  2019cited by this paper
• Longitudinal Study of Visual Function in Vogt-Koyanagi-Harada Disease Using Full-Field Electroretinography.

  2018cited by this paper
• Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of ‘sunset glow fundus’ in initial‐onset acute uveitis associated with Vogt–Koyanagi–Harada disease

  2017influential reference
• Retinal oxygen: from animals to humans.

  2017cited by this paper
• Relationship between choroidal blood flow velocity and choroidal thickness during systemic corticosteroid therapy for Vogt–Koyanagi–Harada disease

  2015cited by this paper
• What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review

  2013cited by this paper
• The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt–Koyanagi–Harada disease

  2012cited by this paper
• Retinal functional changes measured by microperimetry after immunosuppressive therapy in patients with Vogt-Koyanagi-Harada disease

  2012cited by this paper
• Elevated choroidal blood flow velocity during systemic corticosteroid therapy in Vogt–Koyanagi–Harada disease

  2008cited by this paper
• Study of macular function by multifocal electroretinography in patients with Vogt-Koyanagi-Harada syndrome.

  2008cited by this paper
• Expression of chemokines and gelatinase B in sympathetic ophthalmia

  2007cited by this paper
• Microperimetry and fundus autofluorescence in patients with early age-related macular degeneration

  2007cited by this paper
• Pathology of Vogt–Koyanagi–Harada disease

  2007cited by this paper
• Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis.

  2006cited by this paper
• Visual function in Vogt-Koyanagi-Harada patients

  2005cited by this paper
• The standardization of uveitis nomenclature (SUN) working group; standardization of uveitis nomenclature for reporting clinical data: Results of the first international workshop

  2005cited by this paper
• Fundus perimetry with the Micro Perimeter 1 in normal individuals: comparison with conventional threshold perimetry.

  2005cited by this paper
• Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.

  2005cited by this paper
• Fixation pattern and macular sensitivity in eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. A microperimetry study

  2003cited by this paper
• Tyrosinase Family Proteins Are Antigens Specific to Vogt-Koyanagi-Harada Disease1

  2000cited by this paper

• No citing papers are available for this paper.